PHASE I/II STUDY OF XCELLERATED T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。检测慢性淋巴细胞白血病患者使用Xcellerated T细胞的安全性并确定其最大耐受剂量。此外，将评估淋巴细胞计数、淋巴结面积和定量免疫球蛋白，以获得治疗效果的初步证据。将通过流式细胞术评价T和B淋巴细胞表型的变化。还将评估T细胞库和抗肿瘤免疫活性的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Test the safety and determine the maximum tolerated dose of Xcellerated T Cells in patients with chronic lymphocytic leukemia. In addition, lymphocyte counts, lymph node area, and quantitative immunoglobulins will be assessed for preliminary evidence of a therapeutic effect. Changes in the phenotype of T and B lymphocytes will be evaluated by flow cytometry. Changes in T cell repertoire and anti-tumor immune activity will also be assessed.